Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Digihep is a branded generic digestive enzyme formulation developed and marketed by Charan Laboratories. It is typically formulated as a syrup containing a combination of fungal diastase (a form of alpha-amylase) and pepsin. Fungal diastase, often derived from *Aspergillus oryzae*, is an enzyme that catalyzes the hydrolysis of complex carbohydrates (starch) into simpler sugars like maltose, thereby assisting in carbohydrate digestion. Pepsin is a proteolytic enzyme that breaks down dietary proteins into smaller peptides. This combination is indicated for the treatment of various digestive disorders, including indigestion, dyspepsia, flatulence, and loss of appetite, by supplementing the body's natural digestive enzymes. While the brand name 'Digihep' suggests both digestive and hepatic support, the primary formulation in Charan Laboratories' portfolio is focused on these digestive enzymes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alpha-amylase + pepsin.